Through selective depletion studies, we established that initial therapeutic tumor regression following aCD40 monotherapy critically depends on CD8 + T cells but not CD4 + T cells, similar to prior data demonstrating that aCD40 can substitute for CD4 + T cell help46. The gene discussed is CD8A; the disease is neoplasm.